Ionotropic and metabotropic glutamate receptor structure and pharmacology

Psychopharmacology

Volumn 179, Issue 1, 2005, Pages 4-29

  Kew, James N C ^a   Kemp, John A ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Evotec Technologies GmbH   (Germany)

Author keywords

Allosteric modulator; AMPA receptor; Kainate receptor; mGlu receptor; mGluR; NMDA receptor

Indexed keywords

1 (4 AMINOPHENYL) 3,4 DIHYDRO 4 METHYL 3 METHYLCARBAMOYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 2,3 PIPERIDINEDICARBOXYLIC ACID; 3 (2 CARBOXY 2 PHENYLETHENYL) 4,6 DICHLORO 1H INDOLE 2 CARBOXYLIC ACID; 3 AMINO 1 HYDROXY 2 PYRROLIDINONE; 4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; 4 PHOSPHONOMETHYLPIPECOLIC ACID; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; 7 CHLORO 3,4 DIHYDRO 3 METHYL 2H 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; 7 CHLORO 4 HYDROXY 3 (3 PHENOXYPHENYL) 2 QUINOLONE; ASPARTIC ACID; CYCLOSERINE; CYCLOTHIAZIDE; DEXTRO SERINE; DIZOCILPINE; GLUTAMATE RECEPTOR; HOMOCYSTEIC ACID; IFENPRODIL; IONOTROPIC RECEPTOR ANTAGONIST; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; QUINOLINIC ACID; TALAMPANEL; TRAXOPRODIL;

CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG STRUCTURE; EPILEPSY; HUMAN; LIGAND BINDING; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ALLOSTERIC REGULATION; ANIMALS; BINDING, COMPETITIVE; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; LIGANDS; RECEPTORS, AMPA; RECEPTORS, KAINIC ACID; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 17744387125     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-2200-z     Document Type: Review

References (240)

1. 6 subtype of metabotropic glutamic acid receptors. J Med Chem 40:3700-3705
2. Alanine A, Bourson A, Buttelmann B, Gill R, Heitz MP, Mutel V, Pinard E, Trube G, Wyler R (2003) 1-Benzyloxy-4,5-dihydro-1H-imidazol-2-yl-amines, a novel class of NR1/2B subtype selective NMDA receptor antagonists. Bioorg Med Chem Lett 13:3155-3159
3. Al-Hallaq RA, Jarabek BR, Fu Z, Vicini S, Wolfe BB, Yasuda RP (2002) Association of NR3A with the N-methyl-D-aspartate receptor NR1 and NR2 subunits. Mol Pharmacol 62:1119-1127
4. Alt A, Weiss B, Ogden AM, Knauss JL, Oler J, Ho K, Large TH, Bleakman D (2004) Pharmacological characterization of glutamatergic agonists and antagonists at recombinant human homomeric and heteromeric kainate receptors in vitro. Neuropharmacology 46:793-806
5. Anis NA, Berry SC, Burton NR, Lodge D (1983) The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 79:565-575
6. Annoura H, Fukunaga A, Uesugi M, Tatsuoka T, Horikawa Y (1996) A novel class of antagonist for metabotropic glutamate receptors, 7-(hydroxyimino) cyclopropachromen-1α-carboxylates. Bioorg Med Chem Lett 6:763-766
7. Anson LC, Chen PE, Wyllie DA, Colquhoun D, Schoepfer R (1998) Identification of amino acid residues of the NR2A subunit that control glutamate potency in recombinant NR1/NR2A NMDA receptors. J Neurosci 18:581-589
8. Anwyl R (1999) Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brains Res Rev 29:83-120
9. Arai AC, Kessler M, Rogers G, Lynch G (2000) Effects of the potent Ampakine CX614 on hippocampal and recombinant AMPA receptors: interactions with cyclothiazide and GYKI 52466. Mol Pharmacol 58:802-813
10. Arai AC, Xia Y-F, Rogers G, Lynch G, Kessler M (2002) Benzamide-type AMPA receptor modulators form two subfamilies with distinct modes of action. J Pharmacol Exp Ther 303:1075-1085
11. Armstrong N, Gouaux E (2000) Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core. Neuron 28:165-181
12. Armstrong N, Sun Y, Chen GQ, Gouaux E (1998) Structure of a glutamate-receptor ligand-binding core in complex with kainate. Nature 395:913-917
13. Auberson YP, Allgeier H, Bischoff S, Lingenhoehl K, Moretti R, Schmutz M (2002) 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition. Bioorg Med Chem Lett 12:1099-1102
14. Baron BM, Harrison BL, Kehne JH, Schmidt CJ, van Giersbergen PL, White HS, Siegel BW, Senyah Y, McCloskey TC, Fadayel GM, Taylor VL, Murawsky MK, Nyce P, Salituro FG (1997) Pharmacological characterization of MDL 105,519, an NMDA receptor glycine site antagonist. Eur J Pharmacol 323:181-192
15. Barton ME, White HS (2004) The effect of CGX-1007 and CI-1041, novel NMDA receptor antagonists, on kindling acquisition and expression. Epilepsy Res 59:1-12
16. Benveniste M, Mayer ML (1991) Kinetic analysis of antagonist action at N-methyl-D-aspartic acid receptors. Two binding sites each for glutamate and glycine. Biophys J 59:560-573
17. Bhave G, Karim F, Carlton SM, Gereau RW (2001) Peripheral group I metabotropic glutamate receptors modulate nociception in mice. Nat Neurosci 4:417-423
18. Bhave G, Nadin BM, Brasier DJ, Glauner KS, Shah RD, Heinemann SF, Karim F, Gereau RW (2003) Membrane topology of a metabotropic glutamate receptor. J Biol Chem 278:30294-30301
19. Birch PJ, Grossman CJ, Hayes AG (1988) 6,7-Dinitro-quinoxaline-2,3-dion and 6-nitro,7-cyano-quinoxaline-2,3-dion antagonise responses to NMDA in the rat spinal cord via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol 156: 177-180
20. Bleakman D, Ballyk BA, Schoepp DD, Palmer AJ, Bath CP, Sharpe EF, Wooley ML, Bufton HW, Kamboj RK, Tarnawa I, Lodge D (1996) Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: stereospecificity and selectivity profiles. Neuropharmacology 35:1689-1702
21. Bleakman D, Gates MR, Ogden AM, Mackowiak M (2002) Kainate receptor agonists, antagonists and allosteric modulators. Curr Pharm Des 8:873-885
22. Bormann J (1989) Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 166: 591-592
23. Bortolotto ZA, Clarke VRJ, Delny CM, Parry MC, Smolders I, Vignes M, Ho KH, Miu P, Brinton BT, Fantaske R, Ogden A, Gates M, Ornstein PL, Lodge D, Bleakman D, Collingridge GL (1999) Kainate receptors are involved in synaptic plasticity. Nature 402:297-301
24. Bowie D, Mayer ML (1995) Inward rectification of both AMPA and kainate subtype glutamate receptors generated by polyamine-mediated ion channel block. Neuron 15:453-462
25. Brabet I, Parmentier M-L, De Colle C, Bockaert J, Acher F, Pin J-P (1998) Comparative effect of L-CCG-I, DCG-IV and γ-carboxy-L-glutamate on all cloned metabotropic glutamate receptor subtypes. Neuropharmacology 37:1043-1051
26. Bräuner-Osborne H, Krogsgaard-Larsen P (1998) Pharmacology of (S)-homoquisqualic acid and (S)-2-amino-5-phosphopentanoic acid [(S)-AP5] at cloned metabotropic glutamate receptors. Br J Pharmacol 123:269-274
27. Bristow LJ, Hutson PH, Kulagowski JJ, Leeson PD, Matheson S, Murray F, Rathbone D, Saywell KL, Thorn L, Watt AP, Tricklebank MD (1996) Anticonvulsant and behavioral profile of L-701,324, a potent, orally active antagonist at the glycine modulatory site on the N-methyl-D-aspartate receptor complex. J Pharmacol Exp Ther 279:492-501
28. 3H] Homoquinolinate binds to a subpopulation of NMDA receptors and to a novel binding site. J Neurochem 71:1464-1470
29. Buttelmann B, Alanine A, Bourson A, Gill R, Heitz MP, Mutel V, Pinard E, Trube G, Wyler R (2003a) 2-(3,4-Dihydro-1H-isoquinolin-2yl)-pyridines as a novel class of NR1/2B subtype selective NMDA receptor antagonists. Bioorg Med Chem Lett 13:829-832
30. Buttelmann B, Alanine A, Bourson A, Gill R, Heitz MP, Mutel V, Pinard E, Trube G, Wyler R (2003b) 4-(3,4-Dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor antagonists. Bioorg Med Chem Lett 13:1759-1762
31. Campbell UC, Lalwani K, Hernandez L, Kinney GG, Conn PJ, Bristow LJ (2004) The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats. Psychopharmacology 175:310-318
32. Carroll FY, Stolle A, Beart PM, Voerste A, Brabet I, Mauler F, Joly C, Antonicek H, Bockaert J, Muller T, Pin J-P, Prezeau L (2001) BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol Pharmacol 59: 965-973
33. Cartmell J, Schoepp DD (2000) Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 75: 889-907
34. Cartmell J, Monn JA, Schoepp DD (1999) The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus D-amphetamine motor behaviours in rats. J Pharmacol Exp Ther 291:161-170
35. Chaperon F, Muller W, Auberson YP, Tricklebank MD, Neijt HC (2003) Substitution for PCP, disruption of prepulse inhibition and hyperactivity induced by N-methyl-D-aspartate receptor antagonists: preferential involvement of the NR2B rather than NR2A subunit. Behav Pharmacol 14:477-487
36. Chappell AS, Sander JW, Brodie MJ, Chadwick D, Lledo A, Zhang D, Bjerke J, Kiesler GM, Arroyo S (2002) A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology 58:1680-1682
37. Chatterton JE, Awobuluyi M, Premkumar LS, Takahashi H, Talantova M, Shin Y, Cui J, Tu S, Sevarino KA, Nakanishi N, Tong G, Lipton SA, Zhang D (2002) Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits. Nature 415:793-798
38. Chenard BL, Bordner J, Butler TW, Chambers LK, Collins MA, De Costa DL, Ducat MF, Dumont ML, Fox CB, Mena EE (1995) (15,25)-1 -(4-hydroxyphenyl)-2-(4- hydroxy-4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses. J Med Chem 38:3138-3145
39. Chenard BL, Menniti FS, Pagnozzi MJ, Shenk KD, Ewing FE, Welch WM (2000) Methaqualone derivatives are potent non-competitive AMPA receptor antagonists. Bioorg Med Chem Lett 10:1203-1205
40. Chiamulera C, Epping-Jordan MP, Zocchi A, Marcon C, Cottiny C, Tacconi S, Corsi M, Orzi F, Conquet F (2001) Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci 4:873-874
41. K5 receptors. J Pharmacol Exp Ther 309:1003-1010
42. Ciabarra AM, Sullivan JM, Gahn LG, Pecht G, Heinemann S, Sevarino KA (1995) Cloning and characterization of chi-1: a developmentally regulated member of a novel class of the ionotropic glutamate receptor family. J Neurosci 10:6498-6508
43. Claiborne CF, McCauley JA, Libby BE, Curtis NR, Diggle HJ, Kulagowski JJ, Michelson SR, Anderson KD, Claremon DA, Freidinger RM, Bednar RA, Mosser SD, Gaul SL, Connolly TM, Condra CL, Bednar B, Stump GL, Lynch JJ, Macaulay A, Wafford KA, Koblan KS, Liverton NJ (2003) Orally efficacious NR2B-selective NMDA receptor antagonists. Bioorg Med Chem Lett 13:697-700
44. Clark BP, Baker SR, Goldsworthy J, Harris JR, Kingston AE (1997) (+)-2-methyl-4-carboxyphenylglycine (LY367385) selectively antagonises metabotropic glutamate mGluR1 receptors. Bioorg Med Chem Lett 7:2777-2780
45. Clarke VRJ, Ballyk BA, Hoo KH, Mandelzys A, Pellizzari A, Bath CP, Thomas J, Sharpe EF, Davies CH, Ornstein PL, Schoepp DD, Kamboj RK, Collingridge GL, Lodge D, Bleakman D (1997) A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission. Nature 389:599-603
46. Clements JD, Westbrook GL (1991) Activation kinetics reveal the number of glutamate and glycine binding sites on the N-methyl-D-aspartate receptor. Neuron 7:605-613
47. Contractor A, Gereau RW, Green T, Heinemann SF (1998) Direct effects of metabotropic glutamate receptor compounds on native and recombinant N-methyl-D-aspartate receptors. Proc Natl Acad Sci U S A 95:8969-8974
48. Contractor A, Swanson GT, Sailer A, O'Gorman S, Heinemann SF (2000) Identification of the kainate receptor subunits underlying modulation of excitatory synaptic transmission in the CA3 region of the hippocampus. J Neurosci 20:8269-8278
49. Contractor A, Sailer AW, Darstein M, Maron C, Xu J, Swanson GT, Heinemann SF (2003) Loss of kainate receptor-mediated heterosynaptic facilitation of mossy-fiber synapses in KA2-/-mice. J Neurosci 23:422-429
50. 3H]-Methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg Med Chem Lett 13:351-354
51. Cosford NDP, Tehrani L, Roppe J, Scheiger E, Smith ND, Anderson J, Bristow L, Brodkin J, Jiang X, McDonald I, Rao S, Washburn M, Varney MA (2003b) 3-[2-Methyl-1,3-thiazol-4yl) ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem 46:204-206
52. Curtis NR, Diggle HJ, Kulagowski JJ, London C, Grimwood S, Hutson PH, Murray F, Richards P, Macaulay A, Wafford KA (2003) Novel N1-(benzyl) cinnamamidine derived NR2B subtype-selective NMDA receptor antagonists. Bioorg Med Chem Lett 13:693-696
53. Danysz W (2002) CX-516 cortex pharmaceuticals. Curr Opin Investig Drugs 3:1081-1088
54. Das S, Sasaki YF, Rothe T, Premkumar LS, Takasu M, Crandall JE, Dikkes P, Conner DA, Rayudu PV, Cheung W, Chen HS, Lipton SA, Nakanishi N (1998) Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A. Nature 393:377-381
55. 7 receptors by proteins that interact with the intracellular C-terminus. Trends Pharmacol Sci 22:355-361
56. Di Fabio R, Capelli AM, Conti N, Cugola A, Donati D, Feriani A, Gastaldi P, Gaviraghi G, Hewkin CT, Micheli F, Missio A, Mugnaini M, Pecunioso A, Quaglia AM, Ratti E, Rossi L, Tedesco G, Trist DG, Reggiani A (1997) Substituted indole-2-carboxylates as in vivo potent antagonists acting as the strychnine-insensitive glycine binding site. J Med Chem 40: 841-850
57. Dingledine R, Borges K, Bowie D, Traynelis SF (1999) The glutamate receptor ion channels. Pharmacol Rev 51:7-61
58. 1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology 36:265-267
59. Donevan SD, McCabe RT (2000) Conantokin G is an NR2B-selective competitive antagonist of N-methyl-D-aspartate receptors. Mol Pharmacol 58:614-623
60. Drejer J, Honore T (1988) New quinoxalinediones show potent antagonism of quisqualate responses in cultured mouse cortical neurons. Neurosci Lett 87:104-108
61. Elting JW, Sulter GA, Kaste M, Lees KR, Diener HC, Hommel M, Versavel M, Teelken AW, De Keyser J (2002) AMPA antagonist ZK200775 in patients with acute ischemic stroke: possible glial cell toxicity detected by monitoring of S-100B serum levels. Stroke 33:2813-2838
62. Escribano A, Ezquerra J, Pedregal C, Rubio A, Yruretagoyena B, Baker SR, Wright RA, Johnson BG, Schoepp DD (1998) (25,4S)-2-Amino-4-(2,2-diphenylethyl) pentanedioic acid selective group 2 metabotropic glutamate receptor antagonist. Bioorg Med Chem Lett 8:765-770
63. Everts I, Villmann C, Hollmann M (1997) N-glycosylation is not a prerequisite for glutamate receptor function but is essential for lectin modulation. Mol Pharmacol 52:861-873
64. Farlow MR (2004) NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease. Geriatrics 59:22-27
65. Feng DF, Doolittle RF (1987) Progressive sequence alignment as a prerequisite to correct phylogenetic trees. J Mol Evol 25:351-360
66. Feng B, Tse HW, Skifter DA, Morley R, Jane DE, Monaghan DT (2004) Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid. Br J Pharmacol 141:508-516
67. Finlayson K, Witchel HJ, McCulloch J, Sharkey J (2004) Acquired QT interval prolongation and HERG: implications for drug discovery and development. Eur J Pharmacol 500:129-142
68. Fischer G, Mutel V, Trube G, Malherbe P, Kew JN, Mohacsi E, Heitz MP, Kemp JA (1997) Ro 25-6981, a highly potent and selective blocker of N-methyl-D- aspartate receptors containing the NR2B subunit: characterization in vitro. J Pharmacol Exp Ther 283:1285-1292
69. Gallyas F, Ball SM, Molnar E (2003) Assembly and cell surface expression of KA-2 subunit-containing kainate receptors. J Neurochem 86:1414-1427
70. Gasparini F, Bruno V, Battaglia G, Lukic T, Leonhardt T, Inderbitzin W, Laurie D, Sommer B, Varney MA, Hess SD, Johnson EC, Kuhn R, Urwyler S, Sauer D, Portet C, Schmutz M, Nicoletti F, Flor PJ (1999a) (R,S)-4- Phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsant and neuroprotective in vivo. J Pharmacol Exp Ther 290:1678-1687
71. Gasparini F, Lingenhohl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H, Heckendorn R, Urwyler S, Varney MA, Johnson EC, Hess SD, Rao SP, Sacaan AI, Santori EM, Velicelebi G, Kuhn R (1999b) 2-Methyl-6- (phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38:1493-1503
72. Gatti S, Knoflach F, Kew JNC, Adam G, Goetschi E, Porter R, Wichmann J, Woltering T, Kemp JA, Mutel V (2001) 8-Arylethynyl-1,3-dihrdro-benzo[b][1,4] diazepin-2-one derivatives are potent non-competitive metabotropic glutamate receptor 2/3 antagonists. Soc Neurosci Abstr 705.10
73. 2+ permeability of AMPA receptors in principal neurons and interneurons in rat CNS. Neuron 15:193-204
74. Gill R, Hargreaves RJ, Kemp JA (1995) The neuroprotective effect of the glycine site antagonist 3A-(+)-cis-4-methyl-HA966 (L-687,414) in a rat model of focal ischaemia. J Cereb Blood Flow Metab 15:197-204
75. Gill R, Alanine A, Bourson A, Buttelmann B, Fischer G, Heitz MP, Kew JN, Levet-Trafit B, Lorez HP, Malherbe P, Miss MT, Mutel V, Pinard E, Roever S, Schmitt M, Trube G, Wybrecht R, Wyler R, Kemp JA (2002) Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl- benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist. J Pharmacol Exp Ther 302:940-948
76. Goudet C, Gaven F, Kniazeff J, Vol C, Liu J, Cohen-Gonsaud M, Acher F, Prezeau L, Pin JP (2004) Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors. Proc Natl Acad Sci U S A 101:378-383
77. Grillon C, Cordova J, Levine LR, Morgan CA (2003) Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology 168:446-454
78. Grimwood S, Wafford KA, Macaulay A, Hutson PH (2002) N-Methyl-D-aspartate receptor subtype-selectivity of homoquinolinate: an electrophysiological and radioligand binding study using both native and recombinant receptors. J Neurochem 82:794-800
79. Harvey SC, Skolnick P (1999) Polyamine-like actions of aminoglycosides at recombinant N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 291:285-291
80. Hayashi Y, Sekiyama N, Nakanishi S, Jane DE, Sunter DC, Birse EF, Udvarhelyi PM, Watkins JC (1994) Analysis of agonist and antagonist activities of phenylglycine derivatives for different cloned metabotropic glutamate receptor subtypes. J Neurosci 14:3370-3377
81. Heidbreder CA, Bianchi M, Lacroix LP, Faedo S, Perdona E, Remelli R, Cavanni P, Crespi F (2003) Evidence that the metabotropic glutamate receptor 5 antagonist MPEP may act as an inhibitor of the norepinephrine transporter in vitro and in vivo. Synapse 50:269-276
82. Hennegriff M, Aria A, Kessler M, Vaderklish P, Mutneja MS, Rogers G, Neve RL, Lynch G (1997) Stable expression of recombinant AMPA receptor subunits: binding affinities and effects of allosteric modulators. J Neurochem 68:2424-2434
83. Henry SA, Lehmann-Masten V, Gasparini F, Geyer MA, Markou A (2002) The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 43:1199-1209
84. Hermans E, Nahorski SR, Challis RAJ (1998) Reversible and non-competitive antagonist profile of CPCCOEt at the human type 1a metabotropic glutamate receptor. Neuropharmacology 37:1645-1647
85. Higgins GA, Ballard TM, Kew JNC, Richards JG, Kemp JA, Adam G, Woltering T, Nakanishi S, Mutel V (2004) Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. Neuropharmacology 46:907-917
86. Hirai H, Kirsch J, Laube B, Betz H, Kuhse J (1996) The glycine binding site of the N-methyl-D-aspartate receptor subunit NR1: identification of novel determinants of co-agonist potentiation in the extracellular M3-M4 loop region. Proc Natl Acad Sci U S A 93:6031-6036
87. Huang D, Poon SF, Chapman DF, Chung J, Cramer M, Reger TS, Roppe JR, Thehrani L, Cosford NDP, Smith ND (2004) 2-(2-[3-(Pyridin-3-yloxy)phenyl]-2H- tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist. Bioorg Med Chem Lett 14: 5473-5476
88. Ikeda K, Nagasawa M, Mori H, Araki K, Sakimura K, Watanabe M, Inoue Y, Mishina M (1992) Cloning and expression of the epsilon 4 subunit of the NMDA receptor channel. FEBS Lett 313:34-38
89. Isa T, Itazawa S, Iino M, Tsuzuki K, Ozawa S (1996) Distribution of neurones expressing inwardly rectifying and Ca(2+)-permeable AMPA receptors in rat hippocampal slices. J Physiol 491:719-733
90. Ishii T, Moriyoshi K, Sugihara H, Sakurada K, Kadotani H, Yokoi M, Akazawa C, Shigemoto R, Mizuno N, Masu M (1993) Molecular characterization of the family of the N-methyl-D-aspartate receptor subunits. J Biol Chem 268:2836-2843
91. Ito I, Tanabe S, Kohda A, Sugiyama H (1990) Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. J Physiol 424:533-543
92. Jane DE, Olverman HJ, Watkins JC (1994) Agonists and competitive antagonists: structure-activity and molecular modelling studies. In: Collingridge GL, Watkins JC (eds) The NMDA receptor. Oxford University Press, New York, p 31
93. Jang MK, Mierke DF, Russek SJ, Farb DH (2004) A steroid modulatory domain on NR2B controls N-methyl-D-aspartate receptor proton sensitivity. Proc Natl Acad Sci U S A 101: 8198-8203
94. Jingami H, Nakanishi S, Morikawa K (2003) Structure of the metabotropic glutamate receptor. Curr Opin Neurobiol 13:271-278
95. Johnson MP, Baez M, Jagdmann GE, Britton TC, Large TH, Callagaro DO, Tizzano JP, Monn JA, Schoepp DD (2003) Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2-trifluroethylsulfonyl) prid-3-ylmethylamine. J Med Chem 46:3189-3192
96. Kemp JA, Kew JN (1998) NMDA receptor antagonists. In: Leff P (ed) Receptor-based drug design. Marcel Dekker, New York, pp 297-321
97. Kemp JA, Leeson P (1993) The glycine site of the NMDA receptor - five years on. TIPS 14:20-25
98. Kemp JA, McKernan RM (2002) NMDA receptor pathways as drug targets. Nat Neurosci 5:1039-1042
99. Kerchner GA, Wilding TJ, Huettner JE, Zhuo M (2002) Kainate receptor subunits underlying presynaptic regulation of transmitter release in the dorsal horn. J Neurosci 22:8010-8017
100. Kew JN, Kemp JA (1998) An allosteric interaction between the NMDA receptor polyamine and ifenprodil sites in rat cultured cortical neurones. J Physiol 512:17-28
101. Kew JN, Richards JG, Mutel V, Kemp JA (1998a) Developmental changes in NMDA receptor glycine affinity and ifenprodil sensitivity reveal three distinct populations of NMDA receptors in individual rat cortical neurons. J Neurosci 18:1935-1943
102. Kew JN, Trube G, Kemp JA (1998b) State-dependent NMDA receptor antagonism by Ro 8-4304, a novel NR2B selective, non-competitive, voltage-independent antagonist. Br J Pharmacol 123:463-472
103. Kew JN, Koester A, Moreau JL, Jenck F, Ouagazzal AM, Mutel V, Richards JG, Trube G, Fischer G, Montkowski A, Hundt W, Reinscheid RK, Pauly-Evers M, Kemp JA, Bluethmann H (2000) Functional consequences of reduction in NMDA receptor glycine affinity in mice carrying targeted point mutations in the glycine binding site. J Neurosci 20:4037-4049
104. Kingston AE, Ornstein PL, Wright RA, Johnson BG, Mayne NG, Burnett JP, Belagaje R, Wu S, Schoepp DD (1998) LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology 37:1-12
105. Kingston AE, Griffey K, Johnson MP, Chamberlain M-J, Kelly G, Tomlinson R, Wright RA, Johnson BG, Schoepp DD, Harris JR, Clark BP, Baker RS, Tizzano JP (2002) Inhibition of group I metabotropic glutamate receptor responses in vivo in rats by a new generation of carboxyphenylglycine-like amino acid antagonists. Neurosci Lett 330:127-130
106. Kinney GG, Burno M, Campbell UC, Hernandez LM, Rodriguez D, Bristow LJ, Conn PJ (2003) Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Ther 306:116-123
107. Kloda A, Clements JD, Lewis RJ, Adams DJ (2004) Adenosine triphosphate acts as both a competitive antagonist and a positive allosteric modulator at recombinant N-methyl-D-aspartate receptors. Mol Pharmacol 65:1386-1396
108. Kniazeff J, Bessis AS, Maurel D, Ansanay H, Prezeau L, Pin J-P (2004) Closed state of both binding domains of homodimeric mGlu receptors is required for full activity. Nat Struct Mol Biol 8:706-713
109. Knoflach F, Mutel V, Jolidon S, Kew JNC, Malherbe P, Vieira E, Wichmann J, Kemp JA (2001) Positive allosteric modulators of metabotropic glutamate 1 receptor: characterisation, mechanism of action, and binding site. Proc Natl Acad Sci USA 98:13402-13407
110. Kohara A, Okada M, Tsutsumi R, Ohno K, Takahashi M, Shimizu-Sasamata M, Shishikura J, Inami H, Sakamoto S, Yamaguchi T (1998) In-vitro characterization of YM872, a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5- methylisoxazole-4-propionate receptor antagonist. J Pharm Pharmacol 50:795-801
111. Kunishima N, Shimada Y, Tsuji Y, Sato T, Yamamoto M, Kumasaka T, Nakanishi S, Jingami H, Morikawa K (2000) Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature 407:971-977
112. Kuryatov A, Laube B, Betz H, Kuhse J (1994) Mutational analysis of the glycine-binding site of the NMDA receptor: structural similarity with bacterial amino acid-binding proteins. Neuron 12:1291-1300
113. Kutsuwada T, Kashiwabuchi N, Mori H, Sakimura K, Kushiya E, Araki K, Meguro H, Masaki H, Kumanishi T, Arakawa M (1992) Molecular diversity of the NMDA receptor channel. Nature 358:36-41
114. Langan YM, Lucas R, Jewell H, Toublanc N, Schaefer H, Sander JWAS, Patsalos PN (2003) Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia 44:46-53
115. Laube B, Hirai H, Sturgess M, Setz H, Kuhse J (1997) Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit. Neuron 18:493-503
116. 3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol 63:1082-1093
117. Lazzaro JT, Paternain AV, Lerma J, Chenard BL, Ewing FE, Huang J, Welch WM, Ganong AH, Menniti FS (2002) Functional characterisation of CP-465,022, a selective, noncompetitive AMPA receptor antagonist. Neuropharmacology 42:143-153
118. Leeson PD, Iversen LL (1994) The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential. J Med Chem 37:4053-4067
119. Lerma J, Paternain AV, Rodriguez-Moreno A, Lopez-Garcia JC (2001) Molecular physiology of kainate receptors. Physiol Rev 81:971-998
120. 2 challenge in patients diagnosed with panic disorder. Neuropharmacology 43:294
121. 3H]LY395153) to native and recombinant AMPA receptors. Neuropharmacology 40:1010-1018
122. Lindsley CW, Wisnoski DD, Leister WH, O'brien JA, Lemaire W, Williams DL Jr, Burno M, Sur C, Kinney GG, Pettibone DJ, Tiller PR, Smith S, Duggan ME, Hartman GD, Conn PJ, Huff JR (2004) Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J Med Chem 47:5825-5828
123. Litchig S, Gasparini F, Rueegg D, Stoehr N, Flor PJ, Vranesic I, Prezeau L, Pin J-P, Thomsen C, Kuhn R (1999) CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signalling without affecting glutamate binding. Mol Pharmacol 55:453-461
124. Liu SJ, Cull-Candy SG (2002) Activity-dependent change in AMPA receptor properties in cerebellar stellate cells. J Neurosci 22:3881-3889
125. Liu QS, Xu Q, Arcuino G, Kang J, Nedergaard M (2004) Astrocyte-mediated activation of neuronal kainate receptors. Proc Natl Acad Sci U S A 101:3172-3177
126. Lynch G (2004) AMPA receptor modulators as cognitive enhancers. Curr Opin Pharmacol 4:4-11
127. Mahanty NK, Sah P (1998) Calcium-permeable AMPA receptors mediate long-term potentiation in interneurons in the amygdala. Nature 394:683-687
128. Maj M, Bruno V, Dragic Z, Yamamoto R, Battaglia G, Inderbitzin W, Stoehr N, Stein T, Gasparini F, Vranesic I, Kuhn R, Nicoletti F, Flor PJ (2003) (-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection. Neuropharmacology 45:895-906
129. Malayev A, Gibbs TT, Farb DH (2002) Inhibition of the NMDA response by pregnenolone sulphate reveals subtype selective modulation of NMDA receptors by sulphated steroids. Br J Pharmacol 135:901-909
130. Malherbe P, Knoflach F, Broger C, Ohresser S, Kratzeisen C, Adam G, Stadler H, Kemp JA, Mutel V (2001) Identification of essential residues involved in the glutamate binding pocket of the group II metabotropic glutamate receptor. Mol Pharmacol 60:944-954
131. Malherbe P, Kratochwil N, Knoflach F, Zenner M-T, Kew JNC, Kratzeisen C, Maerki HP, Adam G, Mutel V (2003a) Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor. J Biol Chem 278:8340-8347
132. Malherbe P, Kratochwil N, Zenner M-T, Piussi J, Diener C, Kratzeisen C, Fischer C, Porter RHP (2003b) Mutational analysis and molecular modeling of the binding site of the metabotropic glutamate 5 receptor negative modulator 2-Methyl-6-(phenylethynyl)-pyridine. Mol Pharmacol 64:823-832
133. Malherbe P, Mutel V, Broger C, Perin-Dureau F, Kemp JA, Neyton J, Paoletti P, Kew JN (2003c) Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the RO 25-6981 binding pocket. J Pharmacol Exp Ther 307:897-905
134. Marino MJ, Conn PJ (2002) Direct and indirect modulation of the N-methyl D-aspartate receptor. Curr Drug Target CNS Neurol Disord 1:1-16
135. Marino MJ, Williams DL, O'Brien JA, Valenti O, McDonald TP, Clements MK, Wang R, DiLella AG, Hess JF, Kinney GG, Conn PJ (2003) Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc Natl Acad Sci U S A 100:13668-13763
136. Masuko T, Kuno T, Kashiwagi K, Kusama T, Williams K, Igarashi K (1999) Stimulatory and inhibitory properties of aminoglycoside antibiotics at N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 290:1026-1033
137. Mathiesen JM, Svendsen N, Brauner-Osborne H, Thomsen C, Ramirez MT (2003) Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol 138:1026-1030
138. Matsuda K, Kamiya Y, Matsuda S, Yuzaki M (2002) Cloning and characterization of a novel NMDA receptor subunit NR3B: a dominant subunit that reduces calcium permeability. Mol Brain Res 100:43-52
139. Mayer ML, Armstrong N (2004) Structure and function of glutamate receptor ion channels. Annu Rev Physiol 66:161-181
140. McBain CJ, Mayer ML (1994) N-Methyl-D-aspartic acid receptor structure and function. Physiol Rev 74:723-760
141. McCauley JA, Theberge CR, Romano JJ, Billings SB, Anderson KD, Claremon DA, Freidinger RM, Bednar RA, Mosser SD, Gaul SL, Connolly TM, Condra CL, Xia M, Cunningham ME, Bednar B, Stump GL, Lynch JJ, Macaulay A, Wafford KA, Koblan KS, Liverton NJ 2004 NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem 47:2089-2096
142. Meguro H, Mori H, Araki K, Kushiya E, Kutsuwada T, Yamazaki M, Kumanishi T, Arakawa M, Sakimura K, Mishina M (1992) Functional characterization of a heteromeric NMDA receptor channel expressed from cloned cDNAs. Nature 357:70-74
143. Menniti FS, Chenard BL, Collins MB, Ducat MF, Elliott ML, Ewing FE, Huang JI, Kelly KA, Lazzaro JT, Pagnozzi MJ, Weeks JL, Welch WM, White WF (2000) Characterisation of the binding site for a novel class of noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonists. Mol Pharmacol 58:1310-1317
144. Menniti FS, Buchan AM, Chenard BL, Critchett DJ, Ganong AH, Guanowsky V, Seymour PA, Welch WM (2003) CP-465,022, a selective noncompetitive AMPA receptor antagonist, blocks AMPA receptors but is not neuroprotective in vivo. Stroke 34:171-176
145. Miu P, Jarvie KR, Radhakrishnan V, Gates MR, Ogden A, Ornstein PL, Zarrinmayeh H, Ho K, Peters D, Grabell J, Gupta A, Zimmerman DM, Bleakman D (2001) Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro. Neuropharmacology 40:976-983
146. Moldrich RX, Beart PM, Jane DE, Chapman AG, Meldrum BS (2001) Anticonvulsant activity of 3,4-decarboxyphenylglycines in DBA/2 mice. Neuropharmacology 40:732-735
147. Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, Howe T, Alt CA, Rhodes GA, Robey RL, Griffey KR, Tizzano JP, Kallman MJ, Helton DR, Schoepp DD (1997) Design, synthesis and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 40:528-537
148. Monn JA, Valli MJ, Massey SM, Hansen MM, Kress TJ, Wepsiec JP, Harkness AR, Grutsch JL, Wright RA, Johnson BG, Andis SL, Kingston A, Tomlinson R, Lewis R, Griffey KR, Tizzano JP, Schoepp DD (1999) Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem 42:1027-1040
149. Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, Lomeli H, Burnashev N, Sakmann B, Seeburg PH (1992) Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 256:1217-1221
150. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH (1994) Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12:529-540
151. More JCA, Nistico R, Dolman NP, Clarke VRJ, Alt AJ, Ogden AM, Buelens FP, Troop HM, Kelland EE, Pilato F, Bleakman D, Bortolotto ZA, Collingridge GL, Jane DE (2004) Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist. Neuropharmacology 47:46-64
152. Moroni F, Lombardi G, Thomsen C, Leonardi P, Attucci S, Peruginelli F, Torregrossa SA, Pellegrini-Giampietro DE, Luneia R, Pellicciari R (1997) Pharmacological characterization of 1-aminoindan-1,5-dicarboxylic acid, a potent mGluR1 antagonist. J Pharmacol Exp Ther 281:721-729
153. Murray TK, Whalley K, Robinson CS, Ward MA, Hicks CA, Lodge D, Vandergriff JL, Baumgarger P, Siuda E, Gates M, Ogden AM, Skolnick P, Zimmerman DM, Nisenbaum ES, Bleakman D, O'Neill MJ (2003) LY503430, a novel α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. J Pharmacol Exp Ther 306:752-762
154. Nahum-Levy R, Fossom LH, Skolnick P, Benveniste M (1999) Putative partial agonist 1-aminocyclopropanecarboxylic acid acts concurrently as a glycine-site agonist and a glutamate-site antagonist at N-methyl-D-aspartate receptors. Mol Pharmacol 56:1207-1218
155. Nakajima Y, Iwakabe H, Akazawa C, Nawa H, Shigemoto R, Mizuno N, Nakanishi S (1993) Molecular characterisation of a novel retinal metabotropic glutamate receptor mGluR6 with a high agonist selectivity for L-2-amino-4-phosphonobutyrate. J Biol Chem 268:11868-11873
156. Nakazato A, Kumagai T, Sakagami K, Yoshikawa R, Suzuki Y, Chaki S, Ito H, Taguchi T, Nakanishi S, Okuyama S (2000) Synthesis, SARs and pharmacological characterisation of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists. J Med Chem 43: 4893-4909
157. Nishi M, Hinds H, Lu HP, Kawata M, Hayashi Y (2001) Motoneuron-specific expression of NR3B, a novel NMDA-type glutamate receptor subunit that works in a dominant-negative manner. J Neurosci 21:RC185
158. O'Brien JA, Lemaire W, Chen T-B, Chang RSL, Jacobson MA, Ha SN, Lindsley CW, Schaffhauser HJ, Sur C, Pettibone DJ, Conn PJ, Williams DL (2003) A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol Pharmacol 64:731-740
159. O'Brien JA, Lemaire W, Wittmann M, Jacobson MA, Ha SN, Wisnoski DD, Lindsley CW, Schaffhauser HJ, Rowe B, Sur C, Duggan ME, Pettibone DJ, Conn PJ, Williams DL (2004) A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J Pharmacol Exp Ther 309:568-577
160. Ohmori J, Sakamoto S, Kubota H, Shimizu-Sasamata M, Okada M, Kawasaki S, Hidaka K, Togami J, Furuya T, Murase K (1994) 6-(1H-Imidazol-1-yl)-7-nitro-2, 3(1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: structure-activity relationships for the AMPA-type non-NMDA receptor. J Med Chem 37:467-475
161. Ohtani K, Tanaka H, Yoneda Y, Yasuda H, Ito A, Nagata R, Nakamura M (2002) In vitro and in vivo antagonistic activities of SM-31900 for the NMDA receptor glycine-binding site. Brain Res 944:165-173
162. O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES (2004) AMPA receptor potentiators for the treatment of CNS disorders. Curr Drug Target CNS Neurol Disord 3:181-194
163. Pagano A, Ruegg D, Litschig S, Stoehr N, Stierlin C, Heinrich M, Floersheim P, Prezeau L, Carroll F, Pin J-P, Cambria A, Vranesic I, Flor PJ, Gasparini F, Kuhn R (2000) The non-competitive antagonists 2-Methyl-6- (phenylethynyl)pyridine and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J Biol Chem 275:33750-33758
164. 2+. Neuron 15:1109-1120
165. Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, Krzascik P, Hartmann S, Danysz W (1995) Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34:1239-1258
166. Pedegral C, Collado I, Escribano A, Ezquerra J, Dominguez C, Mateo AI, Rubio A, Baker SR, Goldsworthy J, Kamboj RK, Ballyk BA, Hoo K, Bleakman D (2000) 4-Alkyl- and 4-cinnamylglutamic acid analogues are potent GluR5 kainate receptor agonists. J Med Chem 43:1958-1968
167. Pelletier JC, Hesson DP, Jones KA, Costa A-M (1996) Substituted 1,2-dihydrophthalazines: potent, selective, and non-competitive inhibitors of the AMPA receptor. J Med Chem 39:343-346
168. Pellicciari R, Luneia R, Costantino G, Marinozzi M, Natalini B, Jakobsen P, Kanstrup A, Lombardi G, Moroni F, Thomsen C (1995) 1-Aminoindan-1,5- dicarboxylic acid: a novel antagonist at phospholipase C-linked metabotropic glutamate receptors. J Med Chem 38:3717-3719
169. Perin-Dureau F, Rachline J, Neyton J, Paoletti P (2002) Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors. J Neurosci 22:5955-5965
170. Pin JP, Galvez T, Prezeau L (2003) Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol Ther 98:325-354
171. Pinard E, Alanine A, Bourson A, Buttelmann B, Heitz M, Mutel V, Gill R, Trube G, Wyler R (2002) 4-Aminoquinolines as a novel class of NR1/2B subtype selective NMDA receptor antagonists. Bioorg Med Chem Lett 12:2615-2619
172. Pinkerton AB, Vernier J-M, Schaffhauser H, Rowe BA, Campbell UC, Rodriguez DE, Lorrain DS, Baccei CS, Daggett LP, Bristow LJ (2004) Phenyl-tetrazolyl acetophenones: discovery of positive allosteric potentiators for the metabotropic glutamate 2 receptor. J Med Chem 47:4595-4599
173. Poon SF, Eastman BW, Chapman DF, Chung J, Cramer M, Holtz G, Cosford ND, Smith ND (2004) 3-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4- methylpyridine: a highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonist. Bioorg Med Chem Lett 14:5477-5480
174. Priestley T, Kemp JA (1994) Kinetic study of the interactions between the glutamate and glycine recognition sites on the N-methyl-D-aspartic acid receptor complex. Mol Pharmacol 46: 1191-1196
175. Priestley T, Marshall GR, Hill RG, Kemp JA (1998) L-687,414, a low efficacy NMDA receptor glycine site partial agonist in vitro, does not prevent hippocampal LTP in vivo at plasma levels known to be neuroprotective. Br J Pharmacol 124:1767-1773
176. Quirk JC, Nisenbaum ES (2002) LY404187: a novel positive allosteric modulator of AMPA receptors. CNS Drug Rev 8:255-282
177. 3H]MK-801 binding to the N-methyl-D-aspartate receptor-ion channel complex by L-glutamate, glycine, and polyamines. J Neurochem 51:830-836
178. Reddy NL, Hu LY, Cotter RE, Fischer JB, Wong WJ, McBurney RN, Weber E, Holmes DL, Wong ST, Prasad R (1994) Synthesis and structure-activity studies of N,N′-diarylguanidine derivatives. N-(1-Naphthyl)-N′-(3-ethylphenyl)- N′-methylguanidine: a new, selective noncompetitive NMDA receptor antagonist. J Med Chem 37:260-267
179. Rigby M, Le Bourdelles B, Heavens RP, Kelly S, Smith D, Butler A, Hammans R, Hills R, Xuereb JH, Hill RG, Whiting PJ, Sirinathsinghji DJ (1996) The messenger RNAs for the N-methyl-D-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain. Neuroscience 73:429-447
180. Rogawski MA, Gryder D, Castaneda D, Yonekawa W, Banks MK, Lia H (2003) GluR5 kainate receptors, seizures, and the amygdala. Ann N Y Acad Sci 985:150-162
181. Romano C, Yang W-L, O'Malley KL (1996) Metabotropic glutamate receptor 5 is a disulfide-linked dimer. J Biol Chem 271: 28612-28616
182. Rosenmund C, Stern-Bach Y, Stevens CF (1998) The tetrameric structure of a glutamate receptor channel. Science 280:1596-1599
183. Rosemund E, Peltekova V, Naples M, Thogersen H, Hampson DR (2002) Molecular determinants of high affinity binding to group III metabotropic glutamate receptors. J Biol Chem 277: 7333-7340
184. Rowley M, Kulagowski JJ, Watt AP, Rathbone D, Stevenson GI, Carling RW, Baker R, Marshall GR, Kemp JA, Foster AC, Grimwood S, Hargreaves R, Hurley C, Saywell KL, Tricklebank MD, Leeson PD (1997) Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists. J Med Chem 40:4053-4068
185. Ruel J, Guitton MJ, Fuel J-L (2002) Negative allosteric modulation of AMPA-preferring receptors by the selective isomer GYKI 53784 (LY303070), a specific non-competitive AMPA antagonist. CNS Drug Rev 8:235-254
186. Sasaki YF, Rothe T, Premkumar LS, Das S, Cui J, Talantova MV, Wong HK, Gong X, Chan SF, Zhang D, Nakanishi N, Sucher NJ, Lipton SA (2002) Characterization and comparison of the NR3A subunit of the NMDA receptor in recombinant systems and primary cortical neurons. J Neurophysiol 87:2052-2063
187. Sato T, Shimada Y, Nagasawa N, Nakanishi S, Jingami J (2003) Amino acid mutagenesis of the ligand binding site and the dinier interface of the metabotropic glutamate receptor 1. J Biol Chem 278:4314-4321
188. Schaffhauser H, Rowe BA, Morales S, Chavez-Noriega LE, Yin R, Jachec C, Rao SP, Bain B, Pinkerton AB, Vernier J-M, Bristow LJ, Varney MA, Dagget LP (2003) Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol Pharmacol 64:798-810
189. Schiffer HH, Swanson GT, Heinemann S (1997) Rat GluR7 and a carboxy-terminal splice variant, BluR7b, are functional kainate receptor subunits with a low sensitivity to glutamate. Neuron 19:1141-1146
190. Schoepp DD, Marek GJ (2002) Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? Curr Drug Targets CNS Neurol Disord 1:215-225
191. Schoepp DD, Goldsworth J, Johnson BG, Salhoff CR, Baker SR (1994) 3,5-Dihydroxyphenylglycine is a highly selective agonist for phosphoinositide-linked metabotropic glutamate receptors in the rat hippocampus. J Neurochem 63:769-772
192. Schoepp DD, Jane DE, Monn JA (1999a) Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38:1431-1476
193. Schoepp DD, Monn JA, Marek GJ, Aghajanian G, Moghadam B (1999b) LY354740: a systemically active mGlu2/mGlu3 receptor agonist. CNS Drug Rev 5:1-12
194. Schoepp DD, Wright RA, Levine LR, Gaydos B, Potter WZ (2003) LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 6:189-197
195. Schorge S, Colquhoun D (2003) Studies of NMDA receptor function and stoichiometry with truncated and tandem subunits. J Neurosci 23:1151-1158
196. 3H]-LY354740 binding to rat mGlu2 and mGlu3 receptors expressed in CHO cells using Semliki Forest virus vectors. Neuropharmacology 39:1700-1706
197. Seeburg PH, Hartner J (2003) Regulation of ion channel/neurotransmitter receptor function by RNA editing. Curr Opin Neurobiol 13:279-283
198. Sekiguchi M, Fleck MW, Mayer ML, Takeo J, Chiba Y, Yamashita S, Wada K (1997) A novel allosteric potentiator of AMPA receptors: 4-[2- (phenylsulfonylamino)ethylthio]-2,6-difluoro-phenoxyacetamide. J Neurosci 17:5760-5771
199. Sekiguchi M, Nishikawa K, Aoki S, Wada K (2002) A desensitization- selective potentiator of AMPA-type glutamate receptors. Br J Pharmacol 136:1033-1041
200. Sheardown MJ, Nielsen EO, Hansen AJ, Jacobsen P, Honore T (1990) 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science 247: 571-574
201. Sheng M, Cummings J, Roldan LA, Jan YN, Jan LY (1994) Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. Nature 368:144-147
202. Shigemoto R, Mizuno N (2000) Metabotropic glutamate receptors- immunocytochemical and in situ hybridisation analysis. In: Ottersen OP, Storm-Mathisen J (eds) Handbook of chemical neuroanatomy 18: glutamate. Elsevier, Amsterdam, pp 63-98
203. Small B, Thomas J, Kemp M, Hoo K, Ballyk B, Deverill M, Ogden AM, Rubio A, Pedegral C, Bleakman D (1998) LY339434, a GluR5 kainate receptor agonist. Neuropharmacology 37:1261-1267
204. Smith ND, Poon SF, Huang D, Green M, King C, Tehrani L, Roppe JR, Chung J, Chapman DP, Cramer M, Cosford ND (2004) Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity. Bioorg Med Chem Lett 14:5481-5484
205. Solyom S, Tarnawa I (2002) Non-competitive AMPA antagonists of 2,3-benzodiazepine type. Curr Pharm Des 8:913-939
206. Spooren W, Gasparini F (2004) mGlu5 receptor antagonists: a novel class of anxiolytics? Drug News Perspect 17:251-257
207. Spooren W, Ballard T, Gasparini F, Amalric M, Mutel V, Schreiber R (2003) Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders. Behav Pharmacol 14:257-277
208. Stachowicz K, Klak K, Klodzinska A, Chojnacka-Wojcik E, Pilc A (2004) Anxiolytic-like effects of PHCCC, an allosteric modulator of mGlu4 receptors, in rats. Eur J Pharmacol 498:153-156
209. Stensbol TB, Madsen U, Krogsgaard-Larsen P (2002) The AMPA receptor binding site: focus on agonists and competitive antagonists. Curr Pharm Des 8:857-872
210. Sun Y, Olson R, Horning M, Armstrong N, Mayer M, Gouaux E (2002) Mechanism of glutamate receptor desensitisation. Nature 417:245-253
211. Suzuki Y, Moriyoshi E, Tsuchiya D, Jingami H (2004) Negative cooperativity of glutamate binding in the dimeric metabotropic glutamate receptor subtype 1. J Biol Chem 279:35526-35534
212. Swanson GT, Green T, Heinemann SF (1998) Kainate receptors exhibit differential sensitivities to (S)-5-iodowillardiine. Mol Pharmacol 53:942-949
213. Szabados T, Gigler G, Gacsalyi I, Gyertyan I, Levay G (2001) Comparison of anticonvulsive and acute neuroprotective activity of three 2,3-benzodiazepine compounds, GYKI 52466, GYKI 53405, and GYKI 53655. Brain Res Bull 55:387-391
214. Takahashi M, Kohara A, Shishikura J, Kawasaki-Yatsugi S, Ni JW, Yatsugi S, Sakamoto S, Okada M, Shimizu-Sasamata M, Yamaguchi T (2002) YM872: a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5- methylisoxazole-4-propionic acid receptor antagonist. CNS Drug Rev 8:337-352
215. Takano K, Tatlisumak T, Formato JE, Carano RA, Bergmann AG, Pullan LM, Bare TM, Sotak CH, Fisher M (1997) Glycine site antagonist attenuates infarct size in experimental focal ischemia. Postmortem and diffusion mapping studies. Stroke 28: 1255-1262
216. Tarnawa I, Bersenyi P, Andrasi F, Botka P, Hamori T, Ling I, Korosi J (1993) Structure-activity relationships of 2,3-benzodiazepine compounds with glutamate antagonistic action. Bioorg Med Chem Lett 3:99-104
217. Thomas NK, Wright RA, Howson PA, Kingston AE, Schoepp DD, Jane DE (2001) (S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord. Neurophamacology 40:311-318
218. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG (1997) The Clustal_X windows interface: flexible strategies for multiple sequence augment aided by quality analysis tools. Nucleic Acids Res 24:4876-4882
219. Thomsen C, Boel E, Suzdak PD (1994) Actions of phenylglycine analogs at subtypes of the metabotropic glutamate receptor family. Eur J Pharmacol 267:77-84
220. 3+. Proc Natl Acad Sci U S A 99:2660-2665
221. Tsuji Y, Shimada Y, Takeshita T, Kajimura N, Nomura S, Sekiyama N, Otomo J, Usukura J, Nakanishi S, Jingami H (2000) Cryptic dimmer interface and domain organization of the extracellular region of metabotropic glutamate receptor subtype 1. J Biol Chem 275:28144-28151
222. Turski L, Huth A, Sheardown M, McDonald F, Neuhaus R, Schneider HH, Dirnagl U, Wiegand F, Jacobsen P, Ottow E (1998) ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma. Proc Natl Acad Sci U S A 95:10960-10965
223. Vamey MA, Cosford NDP, Jachec C, Rao SP, Sacaan A, Lin F-F, Bleicher L, Santori EM, Flor PJ, Allgeier H, Gasparini F, Kuhn R, Hess SD, Velicelebi G, Johnson EC (1999) SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J Pharmacol Exp Ther 290:170-181
224. Wafford KA, Kathoria M, Bain CJ, Marshall G, Le Bourdelles B, Kemp JA, Whiting PJ (1995) Identification of amino acids in the N-methyl-D-aspartate receptor NR1 subunit that contribute to the glycine binding site. Mol Pharmacol 47:374-380
225. Walker K, Reeve A, Bowes M, Winter J, Wotherspoon G, Davis A, Schmid P, Gasparini F, Kuhn R, Urban L (2001) mGlu5 receptors and nociceptive function II. mGlu5 receptors on peripheral sensory neurones mediate inflammatory hyperalgesia. Neuropharmacology 40:10-19
226. Watanabe M, Inoue Y, Sakimura K, Mishina M (1992) Developmental changes in distribution of NMDA receptor channel subunit mRNAs. NeuroReport 3:1138-1140
227. Watanabe M, Inoue Y, Sakimura K, Mishina M (1993) Distinct distributions of five N-methyl-D-aspartate receptor channel subunit messenger RNAs in the forebrain. J Comp Neurol 338:377-390
228. Watkins JC, Krogsgaard-Larsen P, Honore T (1990) Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. Trends Pharmacol Sci 11:25-33
229. Welch WM, Ewing FE, Huang J, Menniti FS, Pagnozzi MJ, Kelly K, Seymour PA, Guanowsky V Guhan S, Guinn MR, Critchett D, Lazzaro J, Ganong AH, DeVries KM, Staigers TL, Chenard BL (2001) Atropisomeric quinazolin-4-one derivatives are potent noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists. Bioorg Med Chem Lett 11:177-181
230. Wenzel A, Fritschy JM, Mohler H, Senke D (1997) NMDA receptor heterogeneity during postnatal development of the rat brain: differential expression of the NR2A, NR2B, and NR2C subunit proteins. J Neurochem 68:469-478
231. Wichmann J, Bleicher K, Vieira E, Woltering T, Knoflach F, Mutel V (2002) Alkyl diphenylacetyl, 9H-xanthene- and 9H-thioxanthene-carbonyl carbamates as positive allosteric modulators of mGlu1 receptors. Farmaco 57:989-992
232. Williams K (1993) Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol 44:851-859
233. Williams K (1997) Modulation and block of ion channels: a new biology of polyamines. Cell Signal 9:1-13
234. Wong EH, Kemp JA, Priestley T, Knight AR, Woodruff GN, Iversen LL (1986) The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci U S A 83:7104-7108
235. Wroblewska B, Wroblewska JT, Pshenichkin S, Surin A, Sullivan SS, Neale JH (1997) N-Acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J Neurochem 69:174-181
236. Yamada KA, Tang C-M (1993) Benzothiadiazides inhibit rapid glutamate receptor desensitization and enhance glutamatergic synaptic currents. J Neurosci 13:3904-3915
237. 3H]N-2-(4-(N- Benzamido)phenyl)propyl-2-propanesulfonamide: a novel AMPA receptor potentiator and radioligand. J Med Chem 44:302-304
238. Zhong J, Carrozza DP, Williams K, Pritchett DB, Molinoff PB (1995) Expression of mRNAs encoding subunits of the NMDA receptor in developing rat brain. J Neurochem 64:531-539
239. Zhou ZL, Cai SX, Whittemore ER, Konkoy CS, Espitia SA, Tran M, Rock DM, Coughenour LL, Hawkinson JE, Boxer PA, Bigge CF, Wise LD, Weber E, Woodward RM, Keana JF (1999) 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl) piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem 42:2993-3000
240. Zhou ZL, Kher SM, Cai SX, Whittemore ER, Espitia SA, Hawkinson JE, Tran M, Woodward RM, Weber E, Keana JF (2003) Synthesis and SAR of novel di- and trisubstituted 1,4-dihydroquinoxaline-2,3-diones related to licostinel (Acea 1021) as NMDA/glycine site antagonists. Bioorg Med Chem 11: 1769-1780